Skip to main content

Table 3 Results of multivariable Cox regression analysis

From: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

Factor Number of patients
included in the relevant step
p-value of the
likelihood ratio test
hazard ratio 95% confidence interval
of hazard ratio
Event free survival     
LDH at diagnosis (abnormal vs. normal) 325 .020 2.155 1.129 - 4.113
MYCN (amplified vs. normal) 264 .009 1.565 1.117 - 2.191
Age at diagnosis (continuous) 334 <.001 1.099 1.054 - 1.146
ASCT (yes vs. no) 334 .016 .647 .453 - .923
Consolidation treatment 334 .068   
   NB90 maintenance vs. MAB ch14.18   .688 1.083 .733 - 1.601
   No consolidation vs. MAB ch14.18   .021 1.625 1.077 - 2.453
Protocol (NB90 vs. NB97) 334 .106   
Overall survival     
LDH at diagnosis (abnormal vs. normal) 325 .016 2.315 1.170 - 4.578
MYCN (amplified vs. normal) 264 <.001 1.182 1.085 - 1.289
Age at diagnosis (continuous) 334 <.001 1.111 1.062 - 1.161
ASCT (yes vs. no) 334 .036 .673 .464 - .975
Consolidation treatment 334 .031   
   NB90 maintenance vs. MAB ch14.18   .182 1.317 .879 - 1.975
   No consolidation vs. MAB ch14.18   .011 1.737 1.134 - 2.661
Protocol (NB90 vs. NB97) 334 .162   
\